The promising combination of negative marker PGC and positive markers MG7‐ Ag and MMP9 could be used as a potential follow‐up panel for monitoring dynamical progression of AG and to improve the detection efficiency of high‐risk individuals of GC, so then to take the necessary interventions on the target population. This evidence concerns the gene MMP9 and gastric cancer.